Eliasson T U, Abramsson L B, Pettersson G T, Damber J E
Department of Urology and Andrology, Umeå University, Sweden.
Scand J Urol Nephrol. 1995 Jun;29(2):183-91. doi: 10.3109/00365599509180560.
One hundred and seventy two patients with benign prostatic hyperplasia (BPH) were treated with transurethral microwave thermotherapy (TUMT) using Prostcare (Bruker Spectrospin). The treatment was performed with an effect of 52 W and a frequency of 915 MHz, which was generally well tolerated and no serious side effects were observed. In the majority of the patients there was an improvement of subjective symptoms with a significant decrease in Madsen and bothering scores after treatment. In the total patient group, Qmax and voided urine volume were increased slightly, but not statistically significantly. The patients were divided in responders and non-responders, based on Madsen symptom score after 3 months or if complementary treatments were necessary during the follow up period of one year. No significant differences between the groups were observed regarding pretreatment variables except that patients in the responder group experienced the treatment more painful than non-responders. Qmax in the responder group was significantly improved at 6 and 12 months follow up. PSA levels increased significantly after the treatment. Routine evaluation using flow rate, estimation of prostatic size, measurement of residual urine volume and cystoscopy does not give sufficient information for predicting treatment outcome.
172例良性前列腺增生（BPH）患者采用Prostcare（布鲁克光谱仪器公司）进行经尿道微波热疗（TUMT）。治疗功率为52W，频率为915MHz，患者总体耐受性良好，未观察到严重副作用。大多数患者主观症状有所改善，治疗后Madsen评分和困扰评分显著降低。在整个患者组中，最大尿流率（Qmax）和排尿量略有增加，但无统计学意义。根据3个月后的Madsen症状评分或在一年随访期内是否需要辅助治疗，将患者分为反应者和无反应者。除反应者组患者比无反应者感觉治疗更疼痛外，两组治疗前变量无显著差异。在6个月和12个月随访时，反应者组的Qmax显著改善。治疗后前列腺特异性抗原（PSA）水平显著升高。使用尿流率、前列腺大小估计、残余尿量测量和膀胱镜检查进行的常规评估，无法为预测治疗结果提供足够信息。
